Did you know that the European Medicines Agency (EMA) approved 42 new active substances (i. e. substance responsible for the activity of a medicine) in 2018, of which 11 oncology drugs, including drugs indicated to treat certain types of breast cancer. Many of these drugs represent significant progress in their therapeutic areas!
For those of you who are interested to learn more, you can find more detail in the annual report 2018 (p52-53) published by the EMA in the link below.
The EMA is the agency responsible for the evaluation, approval and supervision of medicinal products in the EU. The annual report gives a very interesting overview and insight into the mission, activities and responsibilities of the agency to ensure the safety and efficacy of medicines on the market.
No medicine can be prescribed by physicians and/or used by patients without approval/marketing authorization granted by the responsible health authorities.